AbbVie, Bristol-Myers Squibb partner on combo treatment for lung cancer
AbbVie and Bristol-Myers Squibb (BMS) are collaborating on a clinical trial combining both companies’ checkpoint inhibitors to treat relapsed extensive-stage small cell lung cancer (SCLC).
Click on this link for more information.
